# Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT02663440** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **RADIATION:** Hypofractionated IMRT
- **BIOLOGICAL:** Granulocyte-macrophage Colony-stimulating Factor
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02663440
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2017-12
- **Final completion:** —
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663440, "Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02663440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*